The relationship between chronic lymphocytic leukaemia (CLL) and primary malignant neoplasms was evaluated using data from the Hematology Division in Beilinson Medical Center and the Israel Cancer Registry.
Introduction
The relationship between chronic lymphocytic leukaemia (CLL) and primary malignant neoplasms has been evaluated by several studies. An increased incidence of malignant neoplasms has been reported by some investigators'"2 but disputed by others.3'4 To explore further this association, we evaluated retrospectively 81 patients with CLL treated by the Hematology Division of Beilinson Medical Center. The results of this study are reported below.
Materials and methods
A series of 81 patients with CLL, diagnosed between 1962 and 1984, were identified from the records of the Hematology Division of Beilinson Medical Center. The criterion for diagnosis ofCLL was a sustained and absolute lymphocytosis of 10 x I09 cells/l in the peripheral blood.5 Bone marrow aspiration and/or biopsy was not done in every patient and was not a prerequisite for the diagnosis. The majority ofpatients received therapy which included alkylating agents (chlorambucil or cyclophosphamide) and prednisone. malignant neoplasms in addition to the CLL (Table  II) . There were three basal (BCC) and three squamous cell (SCC) skin cancers following CLL -a combined cumulative incidence of 1.27 per 100 person-years. Seven other malignancies were diagnosed after CLL, yielding a cumulative incidence of 1.48 per 100 personyears. The cumulative incidence of all cancers (including non-melanoma skin cancers) appearing subsequent to CLL was 2.7/102. Eight additional cancers occurred before CLL diagnosis -a total incidence of 1.12 per 100 person-years or 0.8/102 excluding the nonmelanoma skin cancers.
Among the 7 patients (excluding BCC and SCC) whose associated cancer was subsequent to CLL diagnosis two women had breast cancer and the other two females had brain tumours. The three men all had different cancers: bladder cancer, lung cancer and carcinoma with primary unknown. Comparing the 7 observed cancers to the 4.2 expected (Table III) yielded a ratio of 1.7 which was not statistically significant. The ratio was similar for males (1.8) and females (1.6) and for European-American born (1.7) and Asian-African born (1.6). An increased risk of brain cancer (O/E = 20.0) was observed, but although the risk was statistically significant it was based on only two cases.
Excluding patients having non-melanoma skin cancer, eleven had cancer which occurred either before or after CLL diagnosis, compared to 9.61 expected. Although the total number of observed cancers was very close to that expected (O/E = 1.1) significantly increased risks of melanoma (O/E = 14.3), carcinoma of the gastrointestinal tract (O/E = 4.2) and brain (O/E = 9.5) were seen.
Discussion
The coincidence ofCLL and malignant tumours ofthe skin is well documented2'3'5 (Table IV) . However, there is still controversy revolving around the question of whether patients with CLL also have an increased (Table IV) . Although the numbers are small, the results from our study suggest that subsequent to CLL diagnosis, there is a slight, non-significant increase of second neoplasms over that expected. Since there is no registry of non-melanoma skin cancer in Israel, we were unable to conclude whether the 6 cases observed in our series is higher than expectation. The incidence of 1.27 per 100 person-years of risk is within the range of 0.73 to 3.38 observed in other studies (Table IV The mean time interval from the diagnosis of CLL to the diagnosis of the second, non-haematopoietic neoplasm was reported in one study to be 59 months.9 Since the mean follow-up of our patients was 68 months, it is theoretically possible that a few more cases will be diagnosed in the near future.
In summary, excluding patients with non-melanoma skin tumours, a 1.7 increased risk (statistically not significant) for developing second malignant neoplasms in CLL patients was detected by us. The higher than expected occurrence of brain tumours in our patients has not been reported previously. Significantly increased risks of melanoma and carcinoma of gastrointestinal tract were seen. However, they occurred before CLL diagnosis.
The coexistence of multiple cancers in the same patient, although rare, was diagnosed in four of our patients. These results further support the hypothesis that patients with CLL are prone to develop second neoplasms. 
